These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36734885)

  • 1. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine.
    Zou J; Kurhade C; Patel S; Kitchin N; Tompkins K; Cutler M; Cooper D; Yang Q; Cai H; Muik A; Zhang Y; Lee DY; Şahin U; Anderson AS; Gruber WC; Xie X; Swanson KA; Shi PY
    N Engl J Med; 2023 Mar; 388(9):854-857. PubMed ID: 36734885
    [No Abstract]   [Full Text] [Related]  

  • 2. Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines.
    Li D; Duan M; Wang X; Gao P; Zhao X; Xu K; Gao GF
    N Engl J Med; 2023 Mar; 388(12):1142-1145. PubMed ID: 36856580
    [No Abstract]   [Full Text] [Related]  

  • 3. Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection.
    Carr EJ; Wu MY; Gahir J; Harvey R; Townsley H; Bailey C; Fowler AS; Dowgier G; Hobbs A; Herman L; Ragno M; Miah M; Bawumia P; Smith C; Miranda M; Mears HV; Adams L; Haptipoglu E; O'Reilly N; Warchal S; Sawyer C; Ambrose K; Kelly G; Beale R; Papineni P; Corrah T; Gilson R; Gamblin S; Kassiotis G; Libri V; Williams B; Swanton C; Gandhi S; Lv Bauer D; Wall EC;
    Lancet Infect Dis; 2023 Jul; 23(7):781-784. PubMed ID: 37290472
    [No Abstract]   [Full Text] [Related]  

  • 4. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
    Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
    Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
    Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Chang Y; Sutherland A; Montefiori DC; Girard B; Edwards DK; Feng J; Zhou H; Baden LR; Miller JM; Das R
    N Engl J Med; 2022 Oct; 387(14):1279-1291. PubMed ID: 36112399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody Response to Omicron BA.4-BA.5 Bivalent Booster.
    Wang Q; Bowen A; Valdez R; Gherasim C; Gordon A; Liu L; Ho DD
    N Engl J Med; 2023 Feb; 388(6):567-569. PubMed ID: 36630643
    [No Abstract]   [Full Text] [Related]  

  • 7. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.
    Kurhade C; Zou J; Xia H; Liu M; Chang HC; Ren P; Xie X; Shi PY
    Nat Med; 2023 Feb; 29(2):344-347. PubMed ID: 36473500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma.
    Wang Y; Ma Y; Xu Y; Liu J; Li X; Chen Y; Chen Y; Xie J; Xiao L; Xiang Z; Wu F; Huang J
    Emerg Microbes Infect; 2022 Dec; 11(1):424-427. PubMed ID: 35001836
    [No Abstract]   [Full Text] [Related]  

  • 9. Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
    Winokur P; Gayed J; Fitz-Patrick D; Thomas SJ; Diya O; Lockhart S; Xu X; Zhang Y; Bangad V; Schwartz HI; Denham D; Cardona JF; Usdan L; Ginis J; Mensa FJ; Zou J; Xie X; Shi PY; Lu C; Buitrago S; Scully IL; Cooper D; Koury K; Jansen KU; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Kitchin N;
    N Engl J Med; 2023 Jan; 388(3):214-227. PubMed ID: 36652353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
    Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
    Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis.
    Martin P; Clarke C
    EBioMedicine; 2021 Sep; 71():103567. PubMed ID: 34454401
    [No Abstract]   [Full Text] [Related]  

  • 12. Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1.
    Miller J; Hachmann NP; Collier AY; Lasrado N; Mazurek CR; Patio RC; Powers O; Surve N; Theiler J; Korber B; Barouch DH
    N Engl J Med; 2023 Feb; 388(7):662-664. PubMed ID: 36652339
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
    Zhou X; Wang H; Ji Q; Du M; Liang Y; Li H; Li F; Shang H; Zhu X; Wang W; Jiang L; Stepanov AV; Ma T; Gong N; Jia X; Gabibov AG; Lou Z; Lu Y; Guo Y; Zhang H; Yang X
    Protein Cell; 2021 Oct; 12(10):818-823. PubMed ID: 33909239
    [No Abstract]   [Full Text] [Related]  

  • 14. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
    Moyo-Gwete T; Madzivhandila M; Makhado Z; Ayres F; Mhlanga D; Oosthuysen B; Lambson BE; Kgagudi P; Tegally H; Iranzadeh A; Doolabh D; Tyers L; Chinhoyi LR; Mennen M; Skelem S; Marais G; Wibmer CK; Bhiman JN; Ueckermann V; Rossouw T; Boswell M; de Oliveira T; Williamson C; Burgers WA; Ntusi N; Morris L; Moore PL
    N Engl J Med; 2021 Jun; 384(22):2161-2163. PubMed ID: 33826816
    [No Abstract]   [Full Text] [Related]  

  • 15. Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines.
    Zhao X; Zhang R; Qiao S; Wang X; Zhang W; Ruan W; Dai L; Han P; Gao GF
    N Engl J Med; 2022 Jul; 387(3):277-280. PubMed ID: 35793198
    [No Abstract]   [Full Text] [Related]  

  • 16. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
    Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
    Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease.
    Yau K; Kurtesi A; Qi F; Delgado-Brand M; Tursun TR; Hu Q; Dhruve M; Kandel C; Enilama O; Levin A; Jiang Y; Hardy WR; Yuen DA; Perl J; Chan CT; Leis JA; Oliver MJ; Colwill K; Gingras AC; Hladunewich MA
    Nat Commun; 2023 Sep; 14(1):6041. PubMed ID: 37758707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters.
    Collier AY; Miller J; Hachmann NP; McMahan K; Liu J; Bondzie EA; Gallup L; Rowe M; Schonberg E; Thai S; Barrett J; Borducchi EN; Bouffard E; Jacob-Dolan C; Mazurek CR; Mutoni A; Powers O; Sciacca M; Surve N; VanWyk H; Wu C; Barouch DH
    N Engl J Med; 2023 Feb; 388(6):565-567. PubMed ID: 36630611
    [No Abstract]   [Full Text] [Related]  

  • 19. Pfizer COVID vaccine protects against worrying coronavirus variants.
    Callaway E
    Nature; 2021 May; 593(7859):325-326. PubMed ID: 33963317
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
    Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA
    Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.